New hope for dangerous pregnancy condition
NCT ID NCT06333652
Summary
This study is testing whether the medication ravulizumab can help control severe preeclampsia and HELLP syndrome, dangerous blood pressure disorders that can occur during pregnancy. The trial will involve 14 pregnant individuals who develop these conditions before 34 weeks of pregnancy. Researchers will measure how the medication affects pregnancy duration and various blood markers to see if it helps manage these serious complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
Locations
-
Mayo Clinic Minnesota
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.